BioSpace News Archive

Innovent Biologics, Inc. announced the final analysis results of ORIENT-16, the Phase 3 study evaluating sintilimab in combination with chemotherapy compared to chemotherapy for the first-line treatment of advanced or metastatic gastric or gastroesophageal junction cancer at the American Association for Cancer Research Annual Meeting 2023.

Ascentage Pharma announced that it had released results from three preclinical studies of the company’s China-approved novel third-generation BCR-ABL inhibitor olverembatinib, and two key investigational apoptosis-targeted drug candidates of Ascentage Pharma, the Bcl-2 inhibitor lisaftoclax and the MDM2-p53 inhibitor alrizomadlin, in Poster Presentations at the 2023 AACR Annual Meeting.

Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research Annual Meeting.

City of Hope will showcase breakthrough research and innovative studies at this year’s American Association for Cancer Research (AACR) Annual Meeting, which takes place April 14 to 19 in Orlando, Florida.

Merus N.V. today announced interim clinical data as of a February 1, 2023 data cutoff, from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in previously treated head and neck squamous cell carcinoma (HNSCC).

ReCode Therapeutics announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the second set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory

Kiora Pharmaceuticals (NASDAQ: KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the Ocular Presentations of Rheumatoid Arthritis and other autoimmune diseases (OPRA+).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therapeutic potency of “naked” to AccumTM-linked mRNA in immunocompetent mice.

Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its ENIGMACTM macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting, AACR 2023, April 14-19, Florida.